Olpha
Private Company
Funding information not available
Overview
Olpha, founded in 2018 and headquartered in Vienna, is a rapidly growing, integrated pharmaceutical company with a legacy spanning over 50 years through its group entities. It combines internal R&D for APIs and finished dosage forms with a substantial B2B services arm, including contract manufacturing and co-development. With a team of over 850 specialists, the company is commercial-stage, generating revenue from its own branded generics portfolio and partnership services, while actively expanding its geographic footprint into regions like Latin America.
Technology Platform
Integrated small molecule R&D and manufacturing platform encompassing API synthesis, intermediate production, and final dosage form development.
Opportunities
Risk Factors
Competitive Landscape
Operates in the highly competitive global generics and pharmaceutical manufacturing services market, competing against large multinational generics companies (e.g., Teva, Sandoz) and specialized CDMOs. Differentiates through integrated API-to-product capabilities and a focus on European quality standards for a broad geographic footprint.